120 related articles for article (PubMed ID: 38303092)
1. Correction: The key cellular senescence related molecule RRM2 regulates prostate cancer progression and resistance to docetaxel treatment.
Cheng B; Li L; Wu Y; Luo T; Tang C; Wang Q; Zhou Q; Wu J; Lai Y; Zhu D; Du T; Huang H
Cell Biosci; 2024 Feb; 14(1):17. PubMed ID: 38303092
[No Abstract] [Full Text] [Related]
2. The key cellular senescence related molecule RRM2 regulates prostate cancer progression and resistance to docetaxel treatment.
Cheng B; Li L; Wu Y; Luo T; Tang C; Wang Q; Zhou Q; Wu J; Lai Y; Zhu D; Du T; Huang H
Cell Biosci; 2023 Nov; 13(1):211. PubMed ID: 37968699
[TBL] [Abstract][Full Text] [Related]
3. LncRNA SNHG4 promotes prostate cancer cell survival and resistance to enzalutamide through a let-7a/RREB1 positive feedback loop and a ceRNA network.
Dong Q; Qiu H; Piao C; Li Z; Cui X
J Exp Clin Cancer Res; 2023 Aug; 42(1):209. PubMed ID: 37596700
[TBL] [Abstract][Full Text] [Related]
4. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
Boukovinas I; Papadaki C; Mendez P; Taron M; Mavroudis D; Koutsopoulos A; Sanchez-Ronco M; Sanchez JJ; Trypaki M; Staphopoulos E; Georgoulias V; Rosell R; Souglakos J
PLoS One; 2008; 3(11):e3695. PubMed ID: 19002265
[TBL] [Abstract][Full Text] [Related]
5. Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer.
Aird KM; Li H; Xin F; Konstantinopoulos PA; Zhang R
Cell Cycle; 2014; 13(2):199-207. PubMed ID: 24200970
[TBL] [Abstract][Full Text] [Related]
6. Cross-Linked Polyphenol-Based Drug Nano-Self-Assemblies Engineered to Blockade Prostate Cancer Senescence.
Nagesh PKB; Chowdhury P; Hatami E; Kumari S; Kashyap VK; Tripathi MK; Wagh S; Meibohm B; Chauhan SC; Jaggi M; Yallapu MM
ACS Appl Mater Interfaces; 2019 Oct; 11(42):38537-38554. PubMed ID: 31553876
[TBL] [Abstract][Full Text] [Related]
7. Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis.
Guccini I; Revandkar A; D'Ambrosio M; Colucci M; Pasquini E; Mosole S; Troiani M; Brina D; Sheibani-Tezerji R; Elia AR; Rinaldi A; Pernigoni N; Rüschoff JH; Dettwiler S; De Marzo AM; Antonarakis ES; Borrelli C; Moor AE; Garcia-Escudero R; Alajati A; Attanasio G; Losa M; Moch H; Wild P; Egger G; Alimonti A
Cancer Cell; 2021 Jan; 39(1):68-82.e9. PubMed ID: 33186519
[TBL] [Abstract][Full Text] [Related]
8. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.
Souglakos J; Boukovinas I; Taron M; Mendez P; Mavroudis D; Tripaki M; Hatzidaki D; Koutsopoulos A; Stathopoulos E; Georgoulias V; Rosell R
Br J Cancer; 2008 May; 98(10):1710-5. PubMed ID: 18414411
[TBL] [Abstract][Full Text] [Related]
9. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.
Corcoran C; Rani S; O'Driscoll L
Prostate; 2014 Sep; 74(13):1320-34. PubMed ID: 25053345
[TBL] [Abstract][Full Text] [Related]
10. A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2).
Mazzu YZ; Armenia J; Chakraborty G; Yoshikawa Y; Coggins SA; Nandakumar S; Gerke TA; Pomerantz MM; Qiu X; Zhao H; Atiq M; Khan N; Komura K; Lee GM; Fine SW; Bell C; O'Connor E; Long HW; Freedman ML; Kim B; Kantoff PW
Clin Cancer Res; 2019 Jul; 25(14):4480-4492. PubMed ID: 30996073
[TBL] [Abstract][Full Text] [Related]
11. Interferon inducible antiviral MxA is inversely associated with prostate cancer and regulates cell cycle, invasion and Docetaxel induced apoptosis.
Brown SG; Knowell AE; Hunt A; Patel D; Bhosle S; Chaudhary J
Prostate; 2015 Feb; 75(3):266-79. PubMed ID: 25327819
[TBL] [Abstract][Full Text] [Related]
12. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
[TBL] [Abstract][Full Text] [Related]
13. Endothelial Cells Promote Docetaxel Resistance of Prostate Cancer Cells by Inducing ERG Expression and Activating Akt/mTOR Signaling Pathway.
Zhou W; Su Y; Zhang Y; Han B; Liu H; Wang X
Front Oncol; 2020; 10():584505. PubMed ID: 33425737
[TBL] [Abstract][Full Text] [Related]
14. Independent prognostic implications of
Ma C; Luo H; Cao J; Gao C; Fa X; Wang G
J Cancer; 2020; 11(23):7009-7022. PubMed ID: 33123291
[No Abstract] [Full Text] [Related]
15. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes.
Corcoran C; Rani S; O'Brien K; O'Neill A; Prencipe M; Sheikh R; Webb G; McDermott R; Watson W; Crown J; O'Driscoll L
PLoS One; 2012; 7(12):e50999. PubMed ID: 23251413
[TBL] [Abstract][Full Text] [Related]
16. PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance.
Holder SL; Abdulkadir SA
Curr Cancer Drug Targets; 2014; 14(2):105-14. PubMed ID: 24274399
[TBL] [Abstract][Full Text] [Related]
17. Circ_0004087 interaction with SND1 promotes docetaxel resistance in prostate cancer by boosting the mitosis error correction mechanism.
Chen L; Song Y; Hou T; Li X; Cheng L; Li Y; Xing Y
J Exp Clin Cancer Res; 2022 Jun; 41(1):194. PubMed ID: 35659274
[TBL] [Abstract][Full Text] [Related]
18. MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy.
Lu H; Lu S; Yang D; Zhang L; Ye J; Li M; Hu W
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30777929
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of biomarkers and their functions for docetaxel-resistant prostate cancer cells.
Deng L; Gu X; Zeng T; Xu F; Dong Z; Liu C; Chao H
Oncol Lett; 2019 Sep; 18(3):3236-3248. PubMed ID: 31452801
[TBL] [Abstract][Full Text] [Related]
20. Sensitizing the cytotoxic action of Docetaxel induced by Pentoxifylline in a PC3 prostate cancer cell line.
Cancino-Marentes ME; Hernández-Flores G; Ortiz-Lazareno PC; Villaseñor-García MM; Orozco-Alonso E; Sierra-Díaz E; Solís-Martínez RA; Cruz-Gálvez CC; Bravo-Cuellar A
BMC Urol; 2021 Mar; 21(1):38. PubMed ID: 33711972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
